Sean, I was responding to # 1268 (see below). I read that as 44,379,628 issued and outstanding with 25,295,207 reserved to be issued. That adds up to 69,674,835. I assumed that further dilution, or the potential for further dilution, was responsible for the gradually declining price as my experience is that a TSE Listing is a huge BOOST for a stock. And in my experience a company doesn't reserve shares unless they mean to issue them. I assumed this stock would go up at least $1.00 when it had the TSE Listing. Maybe the TSE Listing was already factored into the price because somebody I know as owned this stock since it went public and had heard about a TSE Listing in 1994 as something that was "a couple of months away". But, I hope you're right about $9. I guess it's still a matter of being patient.
To: Bruce Wysocki (1267 )
From: Bruce Wysocki Tuesday, Jul 6 1999 4:48PM ET
Reply # of 1273
TORONTO STOCK EXCHANGE ("TSE-T") INFLAZYME PHARMACEUTICALS
LTD. ("IZP-T") - TSE Bulletin 99-0839; Inflazyme Pharmaceuticals, Original Listing
An application has been granted for the original listing in the Industrial category of 69,674,835 Common shares, of which 44,379,628 Common shares will be issued and outstanding, and 25,295,207 Common shares will be reserved for issuance.
These shares will be listed and posted for trading at the opening on Wednesday, July 7, 1999.
The company is subject to the reporting requirements of section 19.09 of the Exchange's General By-law.
Stock Symbol: "IZP"; CUSIP: 45663E 10 2
Temporary Market Maker:
J. Barr |
